Bugs, Mold, and Deception: FDA Uncovers 'Gross Contamination' at Chinese GLP-1 Drug Factories

In a disturbing exposé, U.S. Food and Drug Administration (FDA) inspectors recently unearthed 'gross contamination' including black mold, insect infestations, and suspicious documentation practices at two Chinese factories supplying crucial ingredients for popular GLP-1 weight-loss drugs. The findings, detailed in reports obtained via a Freedom of Information Act (FOIA) request and released on October 15, 2026, reveal serious lapses at Chengdu Shengnuo Biopharm Co. and Nanjing Chengong Pharmaceutical Co., underscoring significant risks within the global pharmaceutical supply chain. Both facilities have now been hit with an Import Alert, blocking their products from entering the U.S. market. At Chengdu Shengnuo, inspectors witnessed quality control staff trying to hide documents and disposing of product samples, alongside the visible contamination of black mold on equipment and widespread insect activity. Nanjing Chengong, meanwhile, was caught buying Active Pharmaceutical Ingredients (APIs) from other manufacturers and relabeling them with its own approval without proper verification, a red flag previously raised by the FDA about other Chinese suppliers. These factories are key players in manufacturing the APIs semaglutide and tirzepatide for compounded versions of GLP-1 drugs, which are not subject to the same rigorous FDA approval process as brand-name medications from companies like Novo Nordisk and Eli Lilly. The immediate consequence is that U.S. Customs can now detain shipments from these two firms, further tightening the supply for compounded GLP-1 medications already facing high demand and shortages of their approved counterparts. This latest incident, coming on the heels of several FDA warning letters and other import alert issued to Chinese API manufacturers throughout 2025 and 2026 for various Current Good Manufacturing Practice (CGMP) violations, signals intensified scrutiny on foreign drug component suppliers. Patients relying on compounded GLP-1s are urged to verify the legitimacy of their sources, as experts warn of a 'serious accident waiting to happen' amidst ongoing challenges in securing a safe global pharmaceutical supply chain.